Heritable pulmonary arterial hypertension – Diagnostics

Go back

Heritable pulmonary arterial hypertension is a rare genetic condition that affects the blood vessels in the lungs, causing high blood pressure in the arteries between your heart and lungs. Understanding when to seek diagnostic testing and what tests are needed is crucial for early detection and proper management of this serious condition that can affect anyone from young children to older adults.

Introduction: Who Should Undergo Diagnostics

Diagnosing heritable pulmonary arterial hypertension (HPAH) begins with recognizing who should be tested. If you have a family member diagnosed with pulmonary arterial hypertension, which means high blood pressure in the lung arteries, you should talk to your doctor about screening even if you feel healthy. This condition can run in families because of genes passed down from parent to child.[1]

You should seek medical attention if you experience certain warning signs. The most common early symptom is shortness of breath that starts during physical activity and slowly gets worse over time. Other symptoms that should prompt you to see a doctor include unusual tiredness that doesn’t go away, chest pain or pressure, feeling dizzy or fainting, a racing or pounding heartbeat, or swelling in your feet and legs.[2][3]

The challenge with HPAH is that symptoms often develop slowly and may not be noticeable for months or even years. Many people dismiss their early symptoms as simply being out of shape or getting older. By the time symptoms become obvious, the disease may have already progressed. This is why maintaining a high level of suspicion is so important, especially if you have risk factors like a family history of the disease.[2]

⚠️ Important
Research shows that there is often a significant delay between when symptoms first appear and when a diagnosis is made. One French study found an average delay of 27 months from the start of symptoms to getting a proper diagnosis. This delay can be dangerous because HPAH is progressive and gets worse over time without treatment. If you have symptoms like unexplained shortness of breath, especially combined with a family history, don’t wait to seek medical evaluation.[13]

Certain groups of people need to be especially vigilant. Women are twice as likely as men to develop HPAH and are typically diagnosed in their mid-thirties, though the condition can affect people of all ages, including children and the elderly. If you’re a woman with a family history of PAH, regular check-ups and awareness of symptoms becomes even more critical.[2][4]

People who have been diagnosed with or have a history of certain conditions should also be evaluated for PAH. These include connective tissue diseases like lupus, congenital heart disease, liver disease, HIV, or a history of using certain drugs. Additionally, if your doctor hears unusual sounds when listening to your heart or notices signs of heart strain, they may recommend testing for pulmonary hypertension.[2]

Diagnostic Methods

Diagnosing heritable pulmonary arterial hypertension requires multiple steps and different types of tests. The process begins with a detailed conversation with your doctor about your symptoms and medical history. Your doctor will ask when your symptoms started, what makes them better or worse, whether anyone in your family has heart or lung disease, and if you smoke or have other risk factors.[9]

A thorough physical examination is an essential part of the diagnostic process. During this exam, your doctor will listen to your heart and lungs with a stethoscope. They’re checking for specific sounds that indicate problems, such as a loud second heart sound, a right ventricular heave (which means your heart is working harder than normal), or unusual murmurs. They’ll also look for visible signs like swelling in your legs or a bluish tint to your skin, which can indicate low oxygen levels.[2][4]

Blood tests are typically ordered early in the evaluation. These tests serve multiple purposes: they can help identify complications of PAH, rule out other conditions that might be causing your symptoms, and look for underlying diseases associated with PAH. Your doctor might test for markers of autoimmune diseases, liver function, thyroid problems, or HIV, depending on your individual situation.[9][14]

An electrocardiogram, or ECG (sometimes called EKG), is a simple, painless test that records your heart’s electrical activity. This test shows how your heart is beating and can reveal whether the right side of your heart is under strain, which is a warning sign of pulmonary hypertension. Small sticky patches are placed on your chest, arms, and legs, and the machine records your heart’s signals for a few minutes.[9][14]

A chest X-ray provides a picture of your heart, lungs, and chest. While it cannot diagnose HPAH on its own, it can show if your pulmonary arteries are enlarged or if there are other lung conditions that might be causing your symptoms. This test is quick and uses a small amount of radiation to create the image.[9][14]

The echocardiogram is one of the most important initial tests for suspected HPAH. This test uses sound waves to create moving pictures of your beating heart. It’s similar to the ultrasound used to view babies during pregnancy. An echocardiogram shows how blood flows through your heart and heart valves, and it can estimate the blood pressure in your pulmonary arteries. This test is painless and doesn’t involve any needles or radiation. Sometimes, you may be asked to exercise on a treadmill or stationary bike during the test to see how activity affects your heart.[9][13][14]

If the echocardiogram suggests pulmonary hypertension, your doctor will order a right heart catheterization to confirm the diagnosis. This is the gold standard test for diagnosing HPAH. During this procedure, a doctor inserts a thin, flexible tube called a catheter into a blood vessel, usually in your neck. The tube is gently guided through the blood vessel into the right lower chamber of your heart and into the pulmonary artery. This test directly measures the blood pressure in your pulmonary arteries. A diagnosis of HPAH is established when the mean pulmonary artery pressure is greater than 20 mm Hg at rest during this test.[2][9][14]

A CT scan, or computed tomography scan, uses X-rays and a computer to create detailed three-dimensional images of your chest. This test can show enlarged pulmonary arteries and help identify other problems in the lungs that might be causing your symptoms. The machine moves around you as you lie still on a table, and the process takes only a few minutes.[9][14]

A ventilation-perfusion scan, also called a V-Q scan, is another imaging test that may be ordered. This test helps find blood clots in the lungs that could be causing high blood pressure in your pulmonary arteries. It involves breathing in a small amount of radioactive gas and receiving an injection of a radioactive substance to see how air and blood are flowing through your lungs.[9][14]

Lung function tests, also called pulmonary function tests, measure how well your lungs work. During these tests, you breathe into a machine that measures how much air your lungs can hold and how quickly you can move air in and out. These tests help rule out lung diseases that could be causing symptoms similar to HPAH.[9]

Genetic testing plays a special role in diagnosing HPAH. If you have PAH, whether you have a family history or not, your doctor may recommend genetic testing. The most common genetic cause is a mutation in a gene called BMPR2. Mutations in several other genes, including ACVRL1, KCNK3, CAV1, TBX4, and SMAD9, have also been found to cause HPAH, though these are less common. Identifying a genetic mutation helps confirm the diagnosis of heritable PAH and has important implications for your family members, who may also benefit from genetic counseling and testing.[2][4][7]

⚠️ Important
Pulmonary arterial hypertension is classified into five groups based on its causes. Your doctor needs to exclude other forms of pulmonary hypertension before confirming HPAH. These other forms include PH from heart disease (Group 2), PH from lung disease or low oxygen (Group 3), PH from blood clots (Group 4), and PH from various other causes (Group 5). Only Group 1, which includes heritable PAH, is true pulmonary arterial hypertension. This distinction is crucial because treatments differ depending on the type.[2][10]

Diagnostics for Clinical Trial Qualification

When patients with HPAH are being considered for clinical trials, additional standardized testing is typically required. Clinical trials have specific criteria that participants must meet, and these criteria often involve particular test results that demonstrate the severity and type of their condition.

Right heart catheterization is essential for clinical trial enrollment. Trials need precise measurements of pulmonary artery pressures to determine if a patient’s disease severity matches the study’s inclusion criteria. The procedure confirms that the mean pulmonary artery pressure exceeds specific thresholds, typically greater than 20 mm Hg at rest, as defined by updated guidelines.[2][10]

Genetic testing becomes particularly important for clinical trials focused on heritable forms of PAH. Researchers need to confirm whether participants have mutations in specific genes like BMPR2 or other PAH-associated genes. Having documented genetic mutations helps trials study how these specific genetic forms of the disease respond to experimental treatments. Genetic counseling is often provided as part of the trial participation process, since this information has implications not just for the patient but for their family members as well.[2][4]

Clinical trials typically require a thorough assessment of functional capacity. This often includes a six-minute walk test, where patients walk for six minutes and the distance covered is measured. This simple test provides valuable information about how HPAH affects daily functioning and serves as a baseline to measure whether experimental treatments improve physical ability. Patients may also be classified according to the New York Heart Association functional classification (NYHA FC), which ranges from Class I (no limitation of physical activity) to Class IV (symptoms at rest). Most HPAH patients entering clinical trials are in Class III or IV.[4]

Blood tests for clinical trials are more comprehensive than routine diagnostic testing. These may include measurements of specific biomarkers that indicate disease severity or heart stress, such as brain natriuretic peptide (BNP) or N-terminal pro-BNP. These substances are released by the heart when it’s under strain, and their levels can help predict disease progression and treatment response.

Echocardiograms are repeated as part of clinical trial screening to provide detailed baseline information about heart function. Researchers need to document the size and function of the right ventricle (the heart chamber that pumps blood to the lungs), the degree of tricuspid regurgitation (leakage of a heart valve), and estimated pulmonary artery pressures before treatment begins.[9][13]

Risk stratification is an important component of clinical trial qualification. Doctors use a combination of test results to categorize patients as low, intermediate, or high risk. This assessment considers factors like symptoms, exercise capacity, blood test results, and heart function measurements. Clinical trials may specifically target patients in certain risk categories to study whether new treatments can improve outcomes for those groups.[2]

Additional imaging studies, such as cardiac MRI, may be required for some clinical trials. This advanced imaging provides detailed pictures of heart structure and function without using radiation. It can measure the volumes of the heart chambers, assess how well the heart is pumping, and evaluate blood flow patterns in ways that other tests cannot.

Lung function testing is standardized for clinical trial entry to ensure that participants don’t have significant lung disease that could interfere with interpreting study results. These tests help distinguish pure pulmonary arterial hypertension from cases complicated by chronic lung conditions.

Patients considering clinical trial participation should understand that these additional tests serve important purposes. They ensure that only appropriate candidates are enrolled, establish baseline measurements to track treatment effects, and maintain scientific rigor. While the testing process can feel overwhelming, it ultimately helps researchers develop better treatments for future patients with HPAH.

Prognosis and Survival Rate

Prognosis

The outlook for people with heritable pulmonary arterial hypertension depends on several factors, including how early the disease is detected, how severe it is at diagnosis, and how well it responds to treatment. HPAH is described as a progressive condition, which means it gets worse over time without treatment. The disease causes the right side of the heart to work harder to pump blood through the narrowed lung arteries, and eventually this extra strain can weaken the heart muscle and lead to heart failure.[2][4]

Several factors can affect how the disease progresses. Patients with HPAH caused by mutations in certain genes, particularly ACVRL1 or TBX4, tend to have more severe disease that progresses more rapidly and has a poorer prognosis. This form occurs more commonly in children. The disease severity at diagnosis also matters greatly. About 70 percent of HPAH patients present with significant heart failure, classified as New York Heart Association functional class III or IV, which indicates more advanced disease.[4]

HPAH patients generally have more severe clinical presentations compared to other forms of PAH. They tend to have lower cardiac output (meaning the heart pumps less blood), higher pulmonary vascular resistance (meaning greater resistance to blood flow in the lungs), and less response to acute vasodilator testing (a test that checks if medications can temporarily open the lung blood vessels). These characteristics suggest a more challenging disease course.[4]

However, it’s important to understand that early diagnosis and prompt treatment can significantly improve outcomes. With appropriate treatment, many people with HPAH can live longer and maintain a better quality of life than would be possible without intervention. Treatment options have improved considerably in recent years, offering more hope to patients and their families.[6][11]

Without treatment, HPAH can be life-threatening and potentially fatal. The progressive nature of the disease means that symptoms continue to worsen, physical limitations increase, and the risk of heart failure grows. This underscores the critical importance of seeking medical attention when symptoms appear and maintaining regular follow-up care once diagnosed.[2][4][6]

Survival rate

Specific survival statistics for heritable pulmonary arterial hypertension are limited in the provided sources. What is known is that the condition is serious and can be life-threatening without appropriate treatment. The progressive nature of HPAH means that early detection and treatment are crucial for improving survival outcomes.[2][6][11]

Modern treatments have improved the prognosis for PAH patients significantly. Medications can improve quality of life and help patients live longer, though the disease remains a serious condition requiring ongoing medical management. The specific survival rate for an individual patient depends on many factors, including the severity of disease at diagnosis, response to treatment, age, presence of other medical conditions, and the specific genetic mutation involved.[6][11][17]

Ongoing Clinical Trials on Heritable pulmonary arterial hypertension

  • Study on Sotatercept for Improving Heart Function in Patients with Pulmonary Arterial Hypertension

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands
  • Study on Dapagliflozin for Patients with Pulmonary Arterial Hypertension to Improve Exercise Capacity and Heart Function

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark

References

https://phassociation.org/patients/aboutph/genetic-pah/

https://www.ncbi.nlm.nih.gov/books/NBK1485/

https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/symptoms-causes/syc-20350697

https://www.orpha.net/en/disease/detail/275777

https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/learn-about-pulmonary-arterial-hypertension

https://my.clevelandclinic.org/health/diseases/23913-pulmonary-arterial-hypertension

https://medlineplus.gov/genetics/condition/pulmonary-arterial-hypertension/

https://globalgenes.org/subtype/heritable-pulmonary-arterial-hypertension/

https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20350702

https://www.ncbi.nlm.nih.gov/books/NBK1485/

https://my.clevelandclinic.org/health/diseases/23913-pulmonary-arterial-hypertension

https://phassociation.org/patients/aboutph/genetic-pah/

https://www.aafp.org/pubs/afp/issues/2010/0815/p370.html

https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20350702

https://chroniclungdiseases.com/en/news/living-with-pulmonary-hypertension/

https://lungfoundation.com.au/support-resources/resource-hub/living-with-pulmonary-arterial-hypertension-booklet/

https://my.clevelandclinic.org/health/diseases/23913-pulmonary-arterial-hypertension

https://share.upmc.com/2022/08/life-with-pulmonary-hypertension/

https://phassociation.org/newly-diagnosed/faq/

https://www.myphteam.com/resources/living-with-pulmonary-arterial-hypertension-life-hacks-for-everyday-help

https://www.webmd.com/lung/pulmonary-arterial-hypertension

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

What is the difference between pulmonary hypertension and heritable pulmonary arterial hypertension?

Pulmonary hypertension is a general term for high blood pressure in the lungs from any cause, and it’s classified into five groups. Heritable pulmonary arterial hypertension is a specific form that belongs to Group 1 and is caused by genetic mutations inherited from a parent. HPAH can occur even if there’s no known family history when a genetic mutation is identified, or it can run in families with multiple affected members.[1][2]

Do I need genetic testing if I have pulmonary arterial hypertension?

Yes, genetic testing is recommended for patients with PAH, whether there’s a family history or not. Testing should start with screening for mutations in the BMPR2 gene, as this is the most common genetic cause. If no BMPR2 mutation is found but there’s a family history, testing for other PAH-related genes may be done. Identifying a genetic mutation helps confirm the diagnosis and has important implications for family members who may also carry the mutation.[2][4]

Is right heart catheterization the only way to definitively diagnose HPAH?

Yes, right heart catheterization is required to confirm the diagnosis of HPAH. While other tests like echocardiograms can suggest pulmonary hypertension, only a right heart catheterization can directly measure the pressure in your pulmonary arteries and confirm that it exceeds the diagnostic threshold of greater than 20 mm Hg at rest. This test is considered the gold standard for diagnosing all forms of pulmonary arterial hypertension.[2][9][14]

Should my family members be tested if I’m diagnosed with heritable PAH?

Yes, if you’re diagnosed with heritable PAH, your close family members should consider genetic counseling and potentially genetic testing. Heritable PAH is transmitted in an autosomal dominant pattern, meaning children of an affected parent have a 50 percent chance of inheriting the genetic mutation. However, not everyone who inherits the mutation will develop the disease. Family members who carry a mutation can be monitored closely for early signs of PAH, allowing for earlier intervention if the disease develops.[2][4]

Can an echocardiogram alone diagnose heritable pulmonary arterial hypertension?

No, while an echocardiogram is an important screening tool that can estimate pulmonary artery pressure and suggest the presence of pulmonary hypertension, it cannot definitively diagnose HPAH on its own. The diagnosis requires right heart catheterization to directly measure pulmonary artery pressures, exclusion of other causes of pulmonary hypertension, and either genetic testing showing a pathogenic mutation or confirmation of PAH in family members.[2][9][13]

🎯 Key takeaways

  • Heritable PAH can affect anyone in a family, from young children to the elderly, with women twice as likely to develop it, highlighting the importance of family screening when one member is diagnosed
  • The most common early symptom is shortness of breath during activity that slowly worsens, but because symptoms develop gradually over months or years, there’s often a 27-month delay between symptom onset and diagnosis
  • Right heart catheterization is the only definitive test for HPAH diagnosis, measuring pressure directly in the pulmonary artery, with a reading above 20 mm Hg at rest confirming the condition
  • Genetic testing for BMPR2 and other gene mutations is recommended for all PAH patients because identifying a genetic cause confirms heritable PAH and alerts family members to their potential risk
  • The diagnostic process involves multiple tests working together—physical exam, blood tests, ECG, chest X-ray, echocardiogram, and imaging studies—to confirm PAH and rule out other conditions
  • Clinical trial participation requires additional standardized testing beyond routine diagnosis, including detailed heart function measurements, exercise capacity tests, and risk stratification assessments
  • HPAH is progressive and potentially fatal without treatment, but early diagnosis and swift treatment can significantly improve both quality of life and survival, making timely medical attention crucial
  • Not everyone who inherits a PAH-causing gene mutation will develop the disease—only 42 percent of women and 14 percent of men with BMPR2 mutations actually develop symptoms, though they still need monitoring

Connected medications: